A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2013

At a glance

  • Drugs AMG 557 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker
  • Sponsors Amgen
  • Most Recent Events

    • 28 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 13 Jul 2012 Additional location (United Kingdom) added as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top